| Name | The Jefferson |
|---|---|
| Location | 900 North Taylor Street, Arlington, Virginia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 31 |
| Occupancy Rate | 52.26% |
| Medicare ID (CCN) | 495269 |
| Legal Business Name | Welltower Opco Group Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1750334918 |
| Organization Name | SUNRISE SENIOR LIVING SERVICES, INC |
| Doing Business As | THE JEFFERSON |
| Address | 900 N Taylor St, Arlington, VA 22203 |
| Phone Number | 703-516-9455 |
News Archive
Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
A Johns Hopkins Children's Center study of more than 3,000 hospitalized children shows that those colonized but not sick with the antibiotic-resistant bacterium MRSA are at considerable risk for developing full-blown infections.
Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 2 days ago
| NPI Number | 1821585068 |
| Organization Name | WELLTOWER OPCO GROUP LLC |
| Doing Business As | THE JEFFERSON |
| Address | 900 N Taylor St, Arlington, VA 22203 |
| Phone Number | 703-516-9455 |
News Archive
Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
A Johns Hopkins Children's Center study of more than 3,000 hospitalized children shows that those colonized but not sick with the antibiotic-resistant bacterium MRSA are at considerable risk for developing full-blown infections.
Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
A Johns Hopkins Children's Center study of more than 3,000 hospitalized children shows that those colonized but not sick with the antibiotic-resistant bacterium MRSA are at considerable risk for developing full-blown infections.
Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 0 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 0 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 0 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 0 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 93.24 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.45 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 0 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 0 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 0 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 0 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 80.54 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.01 | 82.93 |
News Archive
Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.
Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
A Johns Hopkins Children's Center study of more than 3,000 hospitalized children shows that those colonized but not sick with the antibiotic-resistant bacterium MRSA are at considerable risk for developing full-blown infections.
Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv preprint server.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 2 days ago
Manorcare Health Services-arlington Location: 550 South Carlin Springs Road, Arlington, Virginia 22204 Phone: (703) 379-7200 | |
Regency Care Of Arlington, Llc Location: 1785 South Hayes Street, Arlington, Virginia 22202 Phone: (703) 920-5700 | |
Cherrydale Health And Rehabilitation Center Location: 3710 Lee Highway, Arlington, Virginia 22207 Phone: (703) 243-7640 | |